Source comparison
CJC-1295 no DAC vs CJC-1295 with DAC: Half-Life and Dosing Implications
CJC-1295 without DAC (modified GRF 1-29) has a plasma half-life of approximately 30 minutes. Short enough that it clears the system within 2–3 hours post-injection. This rapid clearance preserves the pulsatile pattern of growth hormone release, which research
This comparison does not assign a generated winner or score.
- CJC-1295 without DAC (modified GRF 1-29) has a plasma half-life of approximately 30 minutes. Short enough that it clears the system within 2–3 hours post-injection. This rapid clearance preserves the pulsatile pattern of growth hormone release, which research from the National Institute on Aging demonstrates is critical for metabolic signaling, lipolysis, and anabolic tissue response. The DAC modification. A synthetic compound that binds albumin. Extends half-life to 6–8 days by creating a slow-release depot effect. Clinically, this allows weekly administration instead of multiple daily doses.
- The tradeoff: CJC-1295 with DAC produces sustained but blunted GH elevation rather than discrete pulses. Studies published in the Journal of Clinical Endocrinology & Metabolism found that pulsatile GH administration produced 40–60% greater lipolytic response compared to continuous infusion at equivalent cumulative dose. The pattern matters as much as the total exposure. For research objectives targeting fat oxidation, muscle protein synthesis, or sleep architecture improvements, the no-DAC version combined with a GHRP like Ipamorelin replicates endogenous physiology more accurately.
- Dosing frequency reflects this mechanism directly. CJC-1295 no DAC protocols typically specify 1–3 administrations per day, timed to align with natural GH secretion peaks (upon waking, post-exercise, and before sleep). The DAC version requires only one injection per week but sacrifices the amplitude and frequency characteristics that drive many of the compound's documented effects. Our experience guiding research teams through protocol design: if the study's endpoint involves circadian rhythm modulation or exercise-induced GH response, the no-DAC formulation is non-negotiable.